The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Drugs in development for toxoplasmosis: advances, challenges, and current status
Open accessAbstract
Abstract: Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T . gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis. Keywords: Toxoplasma gondii , therapeutics, preclinical medicine, experimental medicine, mechanism of action, Apicomplexa
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Epidemiology of and Diagnostic Strategies for Toxoplasmosis
Robert-Gangneux, F., & Dardé, M.-L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05013-11 · Cited by 1,815
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
Pappas, G., Roussos, N., & Falagas, M. E. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.04.003 · Cited by 1,161
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
FATTY ACID SYNTHESIS AND ITS REGULATION
Wakil, S. J., Stoops, J. K., & Joshi, V. C. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.002541 · Cited by 1,026
A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes
Sidik, S. M., Huet, D., Ganesan, S. M., Huynh, M.-H., Wang, T., Nasamu, A. S., Thiru, P., Saeij, J. P. J., Carruthers, V. B., Niles, J. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.019 · Cited by 804
A Plastid of Probable Green Algal Origin in Apicomplexan Parasites
Köhler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. J. M., Palmer, J. D., & Roos, D. S. (1997) · Science · doi:10.1126/science.275.5305.1485 · Cited by 760
Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum
Waller, R. F., Keeling, P. J., Donald, R. G. K., Striepen, B., Handman, E., Lang-Unnasch, N., Cowman, A. F., Besra, G. S., Roos, D. S., & McFadden, G. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12352 · Cited by 714
Outbreak of toxoplasmosis associated with municipal drinking water
Bowie, W. R., King, A. S., Werker, D. H., Isaac-Renton, J. L., Bell, A., Eng, S. B., & Marion, S. A. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11105-3 · Cited by 704
Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome
Porter, S. B., & Sande, M. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272306 · Cited by 670
Regulation of fatty acid biosynthesis in Escherichia coli
Magnuson, K. S., Jackowski, S., Rock, C. O., & Cronan, J. E. (1993) · Microbiological Reviews · doi:10.1128/mmbr.57.3.522-542.1993 · Cited by 654
Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum
Smith, M. H., Ploegh, H. L., & Weissman, J. S. (2011) · Science · doi:10.1126/science.1209235 · Cited by 647
DUBEY, J. P., LAGO, E. G., GENNARI, S. M., SU, C., & JONES, J. L. (2012) · Parasitology · doi:10.1017/s0031182012000765 · Cited by 614
Hoffmann, S., Batz, M. B., & Morris, J. G. (2012) · Journal of Food Protection · doi:10.4315/0362-028x.jfp-11-417 · Cited by 612
A plastid organelle as a drug target in apicomplexan parasites
Fichera, M. E., & Roos, D. S. (1997) · Nature · doi:10.1038/37132 · Cited by 585
Vannier, E., & Krause, P. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1202018 · Cited by 573
Fidock, D. A., & Wellems, T. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10931 · Cited by 518
ToxoDB: an integrated Toxoplasma gondii database resource
Gajria, B., Bahl, A., Brestelli, J., Dommer, J., Fischer, S., Gao, X., Heiges, M., Iodice, J., Kissinger, J. C., Mackey, A. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm981 · Cited by 478
Evidence for the shikimate pathway in apicomplexan parasites
Roberts, F., Roberts, C. W., Johnson, J. J., Kyle, D. E., Krell, T., Coggins, J. R., Coombs, G. H., Milhous, W. K., Tzipori, S., Ferguson, D. J. P., et al. (1998) · Nature · doi:10.1038/31723 · Cited by 452
Sutterland, A. L., Fond, G., Kuin, A., Koeter, M. W. J., Lutter, R., van Gool, T., Yolken, R., Szoke, A., Leboyer, M., & de Haan, L. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12423 · Cited by 429
Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals
Martinez, M. N., McDermott, P. F., & Walker, R. D. (2005) · The Veterinary Journal · doi:10.1016/j.tvjl.2005.07.010 · Cited by 397
Dannemann, B., McCutchan, J. A., Israelski, D., Antoniskis, D., Leport, C., Luft, B., Nussbaum, J., Clumeck, N., Morlat, P., Chiu, J., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-33 · Cited by 360
McLeod, R., Boyer, K., Karrison, T., Kasza, K., Swisher, C., Roizen, N., Jalbrzikowski, J., Remington, J., Heydemann, P., Noble, A. G., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/501360 · Cited by 359
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma
Lourido, S., Shuman, J., Zhang, C., Shokat, K. M., Hui, R., & Sibley, L. D. (2010) · Nature · doi:10.1038/nature09022 · Cited by 342
Demar, M., Ajzenberg, D., Maubon, D., Djossou, F., Panchoe, D., Punwasi, W., Valery, N., Peneau, C., Daigre, J.-L., Aznar, C., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/521246 · Cited by 338
Genetic Divergence of Toxoplasma gondii Strains Associated with Ocular Toxoplasmosis, Brazil
Khan, A., Jordan, C., Muccioli, C., Vallochi, A. L., Rizzo, L. V., Belfort, R., Vitor, R. W. A., Silveira, C., & Sibley, L. D. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1206.060025 · Cited by 329
New Insights into Type II NAD(P)H:Quinone Oxidoreductases
Melo, A. M. P., Bandeiras, T. M., & Teixeira, M. (2004) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.68.4.603-616.2004 · Cited by 270
Katlama, C., De Wit, S., O'Doherty, E., Van Glabeke, M., Clumeck, N., & European Network for Treatment of AIDS (ENTA) Toxoplasmosis Study Group (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.268 · Cited by 253
Apicomplexan plastids as drug targets
McFadden, G. I., & Roos, D. S. (1999) · Trends in Microbiology · doi:10.1016/s0966-842x(99)01547-4 · Cited by 247
Pan, X. S., & Fisher, L. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.471 · Cited by 237
Watts, E., Zhao, Y., Dhara, A., Eller, B., Patwardhan, A., & Sinai, A. P. (2015) · mBio · doi:10.1128/mbio.01155-15 · Cited by 223
Araujo, F. G., Huskinson, J., & Remington, J. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.2.293 · Cited by 220
Walcourt, A., Loyevsky, M., Lovejoy, D. B., Gordeuk, V. R., & Richardson, D. R. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00248-6 · Cited by 211
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites
Bougdour, A., Maubon, D., Baldacci, P., Ortet, P., Bastien, O., Bouillon, A., Barale, J.-C., Pelloux, H., Ménard, R., & Hakimi, M.-A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082826 · Cited by 191
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors
Ojo, K. K., Larson, E. T., Keyloun, K. R., Castaneda, L. J., DeRocher, A. E., Inampudi, K. K., Kim, J. E., Arakaki, T. L., Murphy, R. C., Zhang, L., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1818 · Cited by 191
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis
Doggett, J. S., Nilsen, A., Forquer, I., Wegmann, K. W., Jones-Brando, L., Yolken, R. H., Bordón, C., Charman, S. A., Katneni, K., Schultz, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208069109 · Cited by 187
Self-citationMcLeod, R., Muench, S. P., Rafferty, J. B., Kyle, D. E., Mui, E. J., Kirisits, M. J., Mack, D. G., Roberts, C. W., Samuel, B. U., Lyons, R. E., et al. (2001) · International Journal for Parasitology · doi:10.1016/s0020-7519(01)00111-4 · Cited by 185
McFadden, D. C., Tomavo, S., Berry, E. A., & Boothroyd, J. C. (2000) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(00)00184-5 · Cited by 170
Demar, M., Hommel, D., Djossou, F., Peneau, C., Boukhari, R., Louvel, D., Bourbigot, A. M., Nasser, V., Ajzenberg, D., Dardé, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03648.x · Cited by 168
Jones, J. L., Kruszon‐Moran, D., Rivera, H. N., Price, C. E., & Wilkins, P. P. (2014) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0013 · Cited by 167
Liu, M. C., Lin, T. C., & Sartorelli, A. C. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00098a012 · Cited by 163
Webb, M. E., Smith, A. G., & Abell, C. (2004) · Natural Product Reports · doi:10.1039/b316419p · Cited by 162
HDAC inhibitors in parasitic diseases
Andrews, K. T., Haque, A., & Jones, M. K. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.97 · Cited by 161
A Dynamin Is Required for the Biogenesis of Secretory Organelles in Toxoplasma gondii
Breinich, M. S., Ferguson, D. J. P., Foth, B. J., van Dooren, G. G., Lebrun, M., Quon, D. V. K., Striepen, B., Bradley, P. J., Frischknecht, F., Carruthers, V. B., et al. (2009) · Current Biology · doi:10.1016/j.cub.2009.01.039 · Cited by 152
Hung, A. W., Silvestre, H. L., Wen, S., Ciulli, A., Blundell, T. L., & Abell, C. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903821 · Cited by 151
Meneceur, P., Bouldouyre, M., Aubert, D., Villena, I., Ménotti, J., Sauvage, V., Garin, J.-F., & Derouin, F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01203-07 · Cited by 148
Annual Burden of Ocular Toxoplasmosis in the United States
Jones, J. L., & Holland, G. N. (2010) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2010.09-0664 · Cited by 145
Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii
Murphy, R. C., Ojo, K. K., Larson, E. T., Castellanos-González, A., Perera, B. G. K., Keyloun, K. R., Kim, J. E., Bhandari, J. G., Mueller, N. R., Verlinde, C. L. M. J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100096t · Cited by 144
Acetoacetyl-acyl carrier protein synthase
Jackowski, S., Murphy, C. M., Cronan, J. E., & Rock, C. O. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83280-x · Cited by 140
Artemisinin Induces Calcium-Dependent Protein Secretion in the Protozoan Parasite Toxoplasma gondii
Nagamune, K., Beatty, W. L., & Sibley, L. D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00262-07 · Cited by 138
Sugden, K., Moffitt, T. E., Pinto, L., Poulton, R., Williams, B. S., & Caspi, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148435 · Cited by 129
PS-15: a Potent, Orally Active Antimalarial from a New Class of Folic Acid Antagonists
Canfield, C. J., Milhous, W. K., Ager, A. L., Rossan, R. N., Sweeney, T. R., Lewis, N. J., & Jacobus, D. P. (1993) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1993.49.121 · Cited by 124
Pharmacokinetics and Pharmacodynamics of Hydroxyurea
Gwilt, P. R., & Tracewell, W. G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834050-00002 · Cited by 117
Pidathala, C., Amewu, R. K., Pacorel, B., Nixon, G. L., Gibbons, P. D., Hong, W. D., Leung, S. C., Berry, N. G., Sharma, R., Stocks, P. A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201179h · Cited by 111
Liesen, A. P., de Aquino, T. M., Carvalho, C. S., Lima, V. T., de Araújo, J. M., de Lima, J. G., de Faria, A. R., de Melo, É. J. T., Alves, A. J., Alves, E. W., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.05.017 · Cited by 110
Aspinall, T. V., Joynson, D. H. M., Guy, E. C., Hyde, J. E., & Sims, P. F. G. (2002) · The Journal of Infectious Diseases · doi:10.1086/340577 · Cited by 109
Vaudaux, J. D., Muccioli, C., James, E. R., Silveira, C., Magargal, S. L., Jung, C., Dubey, J. P., Jones, J. L., Doymaz, M. Z., Bruckner, D. A., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/656397 · Cited by 104
Antimalarial 4(1H)-pyridones bind to the Q i site of cytochrome bc 1
Capper, M. J., O’Neill, P. M., Fisher, N. E., Strange, R. W., Moss, D. M., Ward, S. A., Berry, N. G., Lawrenson, A. S., Hasnain, S. S., Biagini, G. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416611112 · Cited by 101
Wang, J., Dixon, S. E., Ting, L.-M., Liu, T., Jeffers, V., Croken, M. M., Calloway, M., Cannella, D., Hakimi, M., Kim, K., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003830 · Cited by 97
Saleh, A., Friesen, J., Baumeister, S., Groß, U., & Bohne, W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00895-06 · Cited by 95
Vidadala, R. S. R., Rivas, K. L., Ojo, K. K., Hulverson, M. A., Zambriski, J. A., Bruzual, I., Schultz, T. L., Huang, W., Zhang, Z., Scheele, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00760 · Cited by 93
Self-citationNgô, H. M., Yang, M., Paprotka, K., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208291200 · Cited by 89
Lawres, L., Garg, A., Kumar, V. P., Bruzual, I., Forquer, I., Renard, I., Virji, A. Z., Boulard, P., Rodriguez, E. X., Allen, A. J., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151519 · Cited by 89
Self-citationWinzer, P. A., Müller, J., Aguado-Martínez, A., Rahman, M., Balmer, V., Manser, V., Ortega‐Mora, L. M., Ojo, K. K., Fan, E., Maly, D. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01236-15 · Cited by 87
Maubon, D., Bougdour, A., Wong, Y., Brenier‐Pinchart, M., Curt, A., Hakimi, M., & Pelloux, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-10 · Cited by 81
Artemisinin-Resistant Mutants of Toxoplasma gondii Have Altered Calcium Homeostasis
Nagamune, K., Moreno, S. N. J., & Sibley, L. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00582-07 · Cited by 79
El-Zawawy, L. A., Said, D. E., Mossallam, S. F., Ramadan, H., & Younis, S. S. (2014) · Experimental Parasitology · doi:10.1016/j.exppara.2014.12.007 · Cited by 76
Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection
Doggett, J. S., Ojo, K. K., Fan, E., Maly, D. J., & Voorhis, W. C. V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01823-13 · Cited by 75
Self-citationToxoplasma gondii Infection: Relationship With Aggression in Psychiatric Subjects
Coccaro, E. F., Lee, R., Groer, M. E., Can, A., Coussons‐Read, M. E., & Postolache, T. T. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09621 · Cited by 75
ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria
Miley, G. P., Pou, S., Winter, R. W., Nilsen, A., Li, Y., Kelly, J. X., Stickles, A. M., Mather, M. W., Forquer, I., Pershing, A. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01183-15 · Cited by 71
Hevener, K. E., Mehboob, S., Su, P.-C., Truong, K., Boci, T., Deng, J., Ghassemi, M., Cook, J. L., & Johnson, M. E. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201168g · Cited by 70
Lourido, S., Zhang, C., Lopez, M. S., Tang, K., Barks, J., Wang, Q., Wildman, S. A., Shokat, K. M., & Sibley, L. D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001314 · Cited by 67
Eschemann, A., Galkin, A. S., Oettmeier, W., Brandt, U., & Kerscher, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411217200 · Cited by 67
Guanabenz Repurposed as an Antiparasitic with Activity against Acute and Latent Toxoplasmosis
Benmerzouga, I., Checkley, L. A., Ferdig, M. T., Arrizabalaga, G., Wek, R. C., & Sullivan, W. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01683-15 · Cited by 66
Vallières, C., Fisher, N. E., Antoine, T., Al‐Helal, M., Stocks, P. A., Berry, N. G., Lawrenson, A. S., Ward, S. A., O’Neill, P. M., Biagini, G. A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00486-12 · Cited by 66
Hencken, C. P., Jones‐Brando, L. V., Bordón, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901857d · Cited by 65
Alday, P. H., Bruzual, I., Nilsen, A., Pou, S., Winter, R. W., Mamoun, C. B., Riscoe, M. K., & Doggett, J. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01866-16 · Cited by 58
Self-citationHolfels, E., Mcauley, J. B., Mack, D. G., Milhous, W. K., & McLeod, R. L. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1392 · Cited by 56
Doliwa, C., Escotte‐Binet, S., Aubert, D., Sauvage, V., Velard, F., Schmid, A., & Villena, I. (2013) · Parasite · doi:10.1051/parasite/2013020 · Cited by 55
Toxoplasmahistone acetylation remodelers as novel drug targets
Vanagas, L., Jeffers, V., Bogado, S. S., Dalmasso, M. C., Sullivan, W. J., & Angel, S. O. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.100 · Cited by 54
Salicylanilide Inhibitors of Toxoplasma gondii
Fomovska, A., Wood, R. D., Mui, E. J., Dubey, J. P., Ferreira, L. R., Hickman, M. R., Lee, P. J., Leed, S. E., Auschwitz, J. M., Welsh, W. J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3007596 · Cited by 48
Jeffers, V., Gao, H., Checkley, L. A., Liu, Y., Ferdig, M. T., & Sullivan, W. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03059-15 · Cited by 47
Chemistry and Biology of Macrolide Antiparasitic Agents
Lee, Y., Choi, J. Y., Fu, H., Harvey, C. J. B., Ravindran, S., Roush, W. R., Boothroyd, J. C., & Khosla, C. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101593u · Cited by 46
Lai, B., Witola, W. H., Bissati, K. E., Zhou, Y., Mui, E. J., Fomovska, A., & McLeod, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208775109 · Cited by 45
Toxoplasmosis Hospitalizations in the United States, 2008, and Trends, 1993-2008
Jones, J. L., & Roberts, J. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir990 · Cited by 44
Beckford, F. A., Thessing, J., Shaloski, M., Mbarushimana, P. C., Brock, A., Didion, J., Woods, J., González‐Sarrías, A., & Seeram, N. P. (2011) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2011.02.029 · Cited by 41
Huang, W., Ojo, K. K., Zhang, Z., Rivas, K. L., Vidadala, R. S. R., Scheele, S., DeRocher, A. E., Choi, R., Hulverson, M. A., Barrett, L. K., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00319 · Cited by 39
Self-citationDubar, F., Wintjens, R. T., Martins-Duarte, É. S., Vommaro, R. C., de Souza, W., Dive, D., Pierrot, C., Pradines, B., Wohlkönig, A., Khalife, J., et al. (2011) · MedChemComm · doi:10.1039/c1md00022e · Cited by 38
Toxoplasma gondii: Fluconazole and itraconazole activity against toxoplasmosis in a murine model
Martins-Duarte, É. S., Lemgruber, L., de Souza, W., & Vommaro, R. C. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2009.12.011 · Cited by 37
Itraconazole affects Toxoplasma gondii endodyogeny
Martins-Duarte, É. S., de Souza, W., & Vommaro, R. C. (2008) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2008.01130.x · Cited by 32
Dzitko, K., Paneth, A., Plech, T., Pawełczyk, J., Stączek, P., Stefańska, J., & Paneth, P. (2014) · Molecules · doi:10.3390/molecules19079926 · Cited by 32
Thiolactomycin analogues as potential anti-Toxoplasma gondii agents
Martins-Duarte, É. S., Jones, S. M., Gilbert, I. H., Atella, G. C., de Souza, W., & Vommaro, R. C. (2009) · Parasitology International · doi:10.1016/j.parint.2009.08.004 · Cited by 31
Martins-Duarte, É. S., Dubar, F., Lawton, P., da Silva, C. F., Soeiro, M. D. N. C., de Souza, W., Biot, C., & Vommaro, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125705 · Cited by 28
Zhou, Y., Fomovska, A., Muench, S. P., Lai, B.-S., Mui, E. J., & McLeod, R. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02225-13 · Cited by 28
Sugi, T., Kawazu, S.-I., Horimoto, T., & Kato, K. (2014) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.12.001 · Cited by 27
Stec, J., Fomovska, A., Afanador, G. A., Muench, S. P., Zhou, Y., Lai, B., Bissati, K. E., Hickman, M. R., Lee, P. J., Leed, S. E., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300050 · Cited by 26
Hydroxyurea inhibits intracellularToxoplasma gondiimultiplication
de Melo, É. J. T., Mayerhoffer, R. O., & de Souza, W. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb09043.x · Cited by 23
Pantothenic Acid Biosynthesis in the Parasite Toxoplasma gondii: a Target for Chemotherapy
Mageed, S. N., Cunningham, F., Hung, A. W., Silvestre, H. L., Wen, S., Blundell, T. L., Abell, C., & McConkey, G. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02640-14 · Cited by 18
1NM-PP1 Treatment of Mice Infected with Toxoplasma gondii
Sugi, T., Kato, K., Kobayashi, K., Kurokawa, H., Takemae, H., Gong, H., Recuenco, F. C., Iwanaga, T., Horimoto, T., & Akashi, H. (2011) · Journal of Veterinary Medical Science · doi:10.1292/jvms.11-0085 · Cited by 15
Wilkinson, C., McPhillie, M. J., Zhou, Y., Woods, S., Afanador, G. A., Rawson, S., Khaliq, F., Prigge, S. T., Roberts, C. W., Rice, D. W., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.066 · Cited by 8
Cited by
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 553
Control of human toxoplasmosis
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 286
Tissue tropism in parasitic diseases
Silva Pereira, S., Trindade, S., De Niz, M., & Figueiredo, L. M. (2019) · Open Biology · doi:10.1098/rsob.190036 · Cited by 85
Toxoplasma gondii vaccine candidates: a concise review
Mamaghani, A. J., Fathollahi, A., Arab-Mazar, Z., kohansal, K., Fathollahi, M., Spotin, A., Bashiri, H., & Bozorgomid, A. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02998-9 · Cited by 51
Promising drug targets and compounds with anti-Toxoplasma gondii activity
Silva, M. D., Teixeira, C., Gomes, P., & Borges, M. (2021) · Microorganisms · doi:10.3390/microorganisms9091960 · Cited by 44
Metadata
- Authors
- Alday, H., & Doggett, J.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-01
- Volume
- Volume11
- Pages
- 273-293
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2580625752
- Cited by
- 321
- References
- 104
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.